Vor Biopharma Inc Ordinary Shares VOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VOR is a good fit for your portfolio.
News
-
Vor Bio to Participate in Upcoming Investor Conferences
-
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
-
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Vor Bio to Participate in Upcoming Investor Conferences
-
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $1.70
- Day Range
- $1.65–1.72
- 52-Week Range
- $1.62–5.70
- Bid/Ask
- $1.68 / $1.76
- Market Cap
- $115.28 Mil
- Volume/Avg
- 154,391 / 340,484
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 168
- Website
- https://www.vorbio.com
Comparables
Valuation
Metric
|
VOR
|
ITOS
|
EQRX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.76 | 0.67 | 0.97 |
Price/Sales | — | 30.67 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
VOR
ITOS
EQRX
Financial Strength
Metric
|
VOR
|
ITOS
|
EQRX
|
---|---|---|---|
Quick Ratio | 8.81 | 13.46 | 18.43 |
Current Ratio | 9.04 | 13.76 | 18.78 |
Interest Coverage | — | — | — |
Quick Ratio
VOR
ITOS
EQRX
Profitability
Metric
|
VOR
|
ITOS
|
EQRX
|
---|---|---|---|
Return on Assets (Normalized) | −41.83% | −12.92% | −15.72% |
Return on Equity (Normalized) | −51.69% | −14.67% | −16.71% |
Return on Invested Capital (Normalized) | −47.03% | −18.54% | −21.31% |
Return on Assets
VOR
ITOS
EQRX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ntfcppycp | Yyqf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rpjdzhvp | Cdwjs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jmjdhcp | Nbpsrg | $97.8 Bil | |
MRNA
| Moderna Inc | Npcsvrzty | Vmml | $41.3 Bil | |
ARGX
| argenx SE ADR | Tjsqfzfrh | Ylp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Khghydjgz | Xpbm | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wlgylrxmt | Tcdcg | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ptmxglh | Cbvqcx | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rskbdvsgd | Zgnzd | $12.5 Bil | |
INCY
| Incyte Corp | Fbpwwqb | Cvrzzl | $11.6 Bil |